Changes in Hong Kong stocks | Innovative drug concept stocks fell in the afternoon 2026 health insurance negotiations ended on the last day for commercial insurance innovative drug catalogue price negotiations

Zhitong Finance App learned that innovative drug concept stocks declined in the afternoon. As of press release, CSPC Group (01093) fell 6.63% to HK$8.795; Cinda Biotech (01801) fell 2.05% to HK$98.15; Nuocheng Jianhua (09969) fell 1.69% to HK$14.51; Rongchang Biotech (09995) fell 1.35% to HK$76.95.

According to the news, according to a report by the Financial Federation, at around 12:00 today, as the last company representative walked out of the National People's Congress Convention Center, the 2026 National Health Insurance Catalogue on-site negotiations and commercial insurance innovative drug catalogue price negotiations were officially completed. The last day of the national talks, this morning, was a commercial insurance innovative drug catalogue price negotiation. In total, representatives from more than 10 companies entered the venue. The first company only took about half an hour to leave the venue.

According to public information, a total of 62 generic drug declarations and 58 passed formal review in the commercial insurance innovative drug catalogue price negotiations this year. Of these, 57 were outside the catalogue and 1 in the catalogue. Rare diseases, tumors, and neurological diseases were still the main players in the declaration, accounting for about 70% of the total. Hengrun Dasen's Reniche Orense injection and Precise Biologic's Pujiolenxol injection, two new CAR-T drugs tried to “break through” for the first time.